Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akeso, Inc. (HK:9926)
HKEX:9926
Holding HK:9926?
Track your performance easily
9926 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$26.45 - HK$78.75
Previous CloseHK$60.85
Volume9.22M
Average Volume (3M)9.13M
Market Cap
HK$54.62B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Mar 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares OutstandingN/A
10 Day Avg. Volume8,425,023
30 Day Avg. Volume9,129,419
Standard Deviation0.20
R-Squared0.10
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$79.75Price Target Upside31.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Akeso, Inc. News
PremiumCompany Announcements
Akeso’s Immunotherapy Drugs Join China’s Reimbursement List
PremiumCompany Announcements
Akeso, Inc. Raises HK$1.924 Billion Through Share Placement
PremiumCompany Announcements
Akeso, Inc. Aims to Raise HK$1.94 Billion in Share Placement
PremiumCompany Announcements
Akeso, Inc.’s New Cholesterol Drug Approved in China
PremiumCompany Announcements
Akeso’s Breakthrough Drug Wins Approval for Gastric CancerPremiumCompany Announcements
Akeso’s Ivonescimab Shows Promise in NSCLC Treatment
PremiumCompany Announcements
Akeso, Inc. Reports Mixed Mid-Year Financial Results
PremiumCompany Announcements
Akeso, Inc. Schedules Key Financial Review MeetingOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
3.16% Mutual Funds
― Other Institutional Investors
91.72% Public Companies and
Individual Investors
9926 FAQ
What was Akeso, Inc.’s price range in the past 12 months?
Akeso, Inc. lowest stock price was HK$26.45 and its highest was HK$78.75 in the past 12 months.
What is Akeso, Inc.’s market cap?
Currently, no data Available
When is Akeso, Inc.’s upcoming earnings report date?
Akeso, Inc.’s upcoming earnings report date is Mar 26, 2025 which is in 94 days.
How were Akeso, Inc.’s earnings last quarter?
Akeso, Inc. released its earnings results on Aug 28, 2024. The company reported -HK$0.299 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.299.
Is Akeso, Inc. overvalued?
According to Wall Street analysts Akeso, Inc.’s price is currently Undervalued.
Does Akeso, Inc. pay dividends?
Akeso, Inc. does not currently pay dividends.
What is Akeso, Inc.’s EPS estimate?
Akeso, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akeso, Inc. have?
Akeso, Inc. has 897,557,200 shares outstanding.
What happened to Akeso, Inc.’s price movement after its last earnings report?
Akeso, Inc. reported an EPS of -HK$0.299 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.897%.
Which hedge fund is a major shareholder of Akeso, Inc.?
Currently, no hedge funds are holding shares in HK:9926
---
Akeso, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.88%
12-Months-Change
Fundamentals
Return on Equity
-14.20%
Trailing 12-Months
Asset Growth
15.62%
Trailing 12-Months
Company Description
Akeso, Inc.
Akeso Inc is a clinical-stage biopharmaceutical company committed to in-house discovery, development, and commercialization of therapies. It is dedicated to addressing global unmet medical needs in oncology, immunology, and other therapeutic areas. The company's drug candidates include AK104 for recurrent or metastatic cervical cancer, Penpulimab (AK105) for the treatment of patients with classical Hodgkin's lymphoma, AK112 for advanced solid tumors, AK101 for the treatment of ulcerative colitis, AK111 for moderate-to-severe psoriasis, Ebronucimab (AK102) for the treatment of patients with a high or very high risk of hypercholesterolemia, and others.
---
9926 Stock 12 Month Forecast
Average Price Target
HK$79.75
▲(31.06% Upside)
Technical Analysis
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Viva Biotech Holdings
―
RemeGen Co. Ltd. Class H
―
China Feihe Limited
―
Best Analysts Covering 9926
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+59.52%
reiterated a buy rating 6 months ago
Copying Tony Ren's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +59.52% per trade.
---